Healthcare is undergoing a profound digital transformation, with continuous patient monitoring, wearable technologies, and artificial intelligence reshaping how diseases are detected, monitored, and treated. At the heart of this evolution are digital biomarkers—objective, measurable physiological and behavioral data collected through connected digital devices that provide valuable insights into a patient’s health.
The global digital biomarkers market is projected to grow from USD 7.41 billion in 2026 to USD 17.73 billion by 2031, registering an impressive CAGR of 19.1% during the forecast period. Market growth is being fueled by the rapid adoption of decentralized clinical trials, increasing use of AI-powered analytics, growing demand for real-world evidence, and expanding applications of wearable health technologies.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=7725399
What Are Digital Biomarkers?
Digital biomarkers are objective health measurements collected through digital technologies such as wearable devices, smartphones, biosensors, and remote monitoring platforms.
Unlike conventional biomarkers obtained through laboratory tests or imaging procedures, digital biomarkers provide continuous, real-time health information outside traditional healthcare settings.
Common digital biomarkers include:
- Heart rate variability
- Physical activity levels
- Sleep quality
- Gait and mobility patterns
- Cognitive performance
- Voice characteristics
- Electrocardiogram (ECG) data
- Respiratory parameters
These measurements enable clinicians and researchers to better understand disease progression, treatment response, and patient outcomes.
Why the Digital Biomarkers Market Is Growing Rapidly
Pharmaceutical Industry Is Driving Adoption
One of the strongest growth drivers is the pharmaceutical and biotechnology industry’s increasing reliance on digital biomarkers throughout clinical development.
Drug developers are integrating digital biomarker platforms to:
- Monitor patients remotely
- Collect continuous real-world data
- Improve clinical endpoint accuracy
- Reduce patient burden
- Enhance trial efficiency
- Support decentralized clinical trials
As clinical research becomes increasingly patient-centric, digital biomarkers are replacing many traditional site-based assessments with continuous remote monitoring.
Decentralized Clinical Trials Are Expanding
Clinical trials are moving beyond hospitals and research centers.
Remote participation has become increasingly common through:
- Wearable sensors
- Smartphone applications
- Connected medical devices
- AI-powered monitoring platforms
More than 130 pharmaceutical and biotechnology organizations have already implemented AI-enabled digital biomarker and sensor technologies across clinical development programs.
Additionally, over 1,300 digital endpoints have been analyzed across clinical trials, with more than 25% now serving as primary clinical endpoints.
This shift is significantly accelerating demand for digital biomarker software platforms.
AI is Enhancing Digital Biomarker Analysis
Artificial Intelligence plays a central role in extracting clinically meaningful insights from massive volumes of patient-generated data.
AI-powered platforms can:
- Detect subtle disease progression
- Predict clinical outcomes
- Identify early warning signs
- Automate data interpretation
- Improve endpoint accuracy
- Support personalized treatment decisions
These capabilities are transforming digital biomarkers into valuable tools for precision medicine and drug development.
Wearable Technology Continues to Expand
The widespread adoption of wearable health devices has significantly increased the availability of continuous patient data.
Modern wearable technologies monitor:
- Cardiac activity
- Movement patterns
- Sleep behavior
- Oxygen saturation
- Stress levels
- Neurological function
These connected devices allow healthcare providers to monitor patients continuously rather than relying solely on periodic clinical visits.
Digital Biomarkers Support Precision Medicine
Precision medicine depends on accurate, continuous, patient-specific data.
Digital biomarkers enable clinicians to:
- Personalize treatment plans
- Monitor therapeutic response
- Detect disease progression earlier
- Improve medication adherence
- Identify patient-specific risk factors
As healthcare becomes increasingly individualized, digital biomarkers are expected to play a central role in future clinical decision-making.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=7725399
Growing Applications Across Therapeutic Areas
Digital biomarkers are rapidly expanding across multiple medical specialties, including:
- Neurology
- Cardiology
- Oncology
- Mental health
- Respiratory diseases
- Parkinson’s disease
- Alzheimer’s disease
- Diabetes management
Researchers increasingly rely on digital endpoints to generate objective evidence that complements traditional clinical assessments.
Industry Innovation Continues to Accelerate
Leading companies continue expanding their digital biomarker capabilities through strategic collaborations, acquisitions, and technology integration.
Recent developments include:
- July 2025: IXICO PLC entered a strategic collaboration with the Global Alzheimer’s Platform Foundation to support the Bio-Hermes-002 study, leveraging advanced neuroimaging analytics to improve Alzheimer’s disease diagnosis and monitor disease progression.
- October 2025: Empatica, Inc. acquired PKG Health, strengthening its neurological monitoring portfolio with wearable-based Parkinson’s disease assessment technologies and expanding its AI-driven digital endpoint capabilities.
- February 2026: Ametris, LLC partnered with AliveCor, Inc. to integrate medical-grade ECG monitoring into the Ametris platform, enabling remote cardiac monitoring and digital cardiac endpoints for decentralized clinical trials.
These developments demonstrate the industry’s strong focus on software-driven innovation and remote patient monitoring.
Company Spotlight
IXICO PLC
IXICO specializes in software-driven digital biomarker solutions for neurodegenerative disease research.
Its advanced neuroimaging analytics platform supports:
- Alzheimer’s disease research
- Neurodegenerative disease monitoring
- Quantitative imaging biomarkers
- Clinical trial optimization
- Disease progression assessment
The company’s solutions improve data quality and enhance the efficiency of neuroscience-focused clinical trials.
Ametris, LLC
Ametris develops software platforms that collect, integrate, and analyze digital biomarker data for clinical research.
Its solutions enable:
- Remote patient monitoring
- Digital endpoint collection
- ECG integration
- Decentralized clinical trials
- AI-supported analytics
Its partnership with AliveCor expands its capabilities in remote cardiovascular monitoring.
Empatica, Inc.
Empatica is a leading provider of AI-powered physiological monitoring platforms.
Its digital health solutions support:
- Neurological monitoring
- Wearable biosensors
- Continuous physiological data collection
- Behavioral biomarkers
- Digital endpoint generation
The acquisition of PKG Health further strengthens its leadership in digital biomarkers for neurodegenerative diseases.
Competitive Landscape
The digital biomarkers market is highly dynamic, with technology companies, digital health innovators, and clinical research platform providers driving innovation.
Leading market participants include:
- IXICO PLC
- Ametris, LLC
- Empatica, Inc.
- AliveCor, Inc.
- CONNEQT Health
- VivoSense
- BioSensics
- Lunit, Inc.
- Akili, Inc.
- Quibim
- Clario
- Proscia, Inc.
- Koneksa Health
- Linus Health
These companies are expanding their software platforms through AI integration, wearable technologies, imaging analytics, remote monitoring, and disease-specific digital biomarker solutions.
Future Outlook
The future of digital biomarkers will be shaped by continued advances in artificial intelligence, wearable technology, and decentralized healthcare.
Key trends expected to drive future growth include:
- Wider adoption of decentralized clinical trials
- Increased use of AI-powered predictive analytics
- Expansion of wearable medical devices
- Greater regulatory acceptance of digital endpoints
- Growth of real-world evidence generation
- Integration with electronic health records
- Expansion of personalized medicine
- Rising demand for remote patient monitoring
As healthcare increasingly embraces digital-first care models, digital biomarkers will become fundamental to clinical research, disease management, and precision medicine.
Conclusion
Digital biomarkers are redefining how patient data is collected, analyzed, and applied across healthcare and life sciences. Their ability to generate continuous, real-world insights is improving clinical trial efficiency, enabling remote patient monitoring, and supporting more personalized healthcare delivery.
With strong adoption by pharmaceutical and biotechnology companies, rapid advances in AI, and growing use of wearable technologies, the market is poised for exceptional growth over the coming years. Companies such as IXICO PLC, Ametris, LLC, Empatica, Inc., AliveCor, CONNEQT Health, Clario, Proscia, Koneksa Health, and Linus Health are leading this transformation by developing software-driven platforms that enable scalable, data-driven healthcare innovation.
As digital health ecosystems continue to evolve, digital biomarkers will play an increasingly important role in accelerating drug development, improving patient outcomes, and shaping the future of connected, precision healthcare.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=7725399